TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00816998

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical Therapy
Description: Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical Therapy
Description: Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
Study: NCT03903289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated red cell exchange
Description: Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual red cell exchange
Description: Active Comparator: Manual red cell exchange
Study: NCT00964756

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5.SSTR/TK.RGD
Description: Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV)
Description: GVC Day 5-18 IV 5 mg/kg BID all groups
Study: NCT02423447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electro-Flo Intervention
Description: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G5 Intervention
Description: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
Study: NCT03903289

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simple red cell transfusion
Description: Active Comparator: Simple red cell transfusion
Study: NCT04683861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
Study: NCT01797874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Experimental

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo arm
Study: NCT00464308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Study: NCT02656875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Study: NCT00396981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Matrix 2® coils for endovascular aneurysm occlusion
Description: endovascular aneurysm occlusion coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GDC® coils for endovascular aneurysm occlusion
Description: endovascular aneurysm occlusion coil
Study: NCT04500054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: The music type was chosen by the patients and researchers did not have any influence on their choices.
Study: NCT03635060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Bridge Plating
Description: This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar locking plating
Description: This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
Study: NCT00693056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (w/o API)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100 5mg
Description: 5 mg/dose of RX-10100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100 10mg
Description: 10 mg/dose of RX-10100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100 15mg
Description: 15 mg/dose of RX-10100
Study: NCT00088218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
Study: NCT02552394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huJ591
Description: HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
Study: NCT01112085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.05mg
Description: Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
Study: NCT03442309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride (SDF)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)
Study: NCT01112085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Description: Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
Study: NCT01546493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
Study: NCT03442309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Glass Ionomer Sealants (GC Fuji IX)
Study: NCT02078778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: 3 months of CPAP treatment
Study: NCT04238130

Intervention type: DIAGNOSTIC_TEST
Intervention: Perioperative ctDNA Dynamic Monitoring
Description: To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
Study: NCT04433247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led Group Intervention
Description: Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
Study: NCT05738083

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Leaning Models
Description: Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model.
Study: NCT02444741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01546493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: qCT
Description: Quantitative computed tomography(QCT) scans using a CT phantom
Study: NCT02444741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01546493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: qCT
Description: Quantitative computed tomography(QCT) scans using a CT phantom

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: qCT
Description: Quantitative computed tomography(QCT) scans using a CT phantom

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: 3D motion analysis to assess hip function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: 3D motion analysis to assess hip function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: 3D motion analysis to assess hip function.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
Study: NCT02395354

Intervention type: DEVICE
Group type: OTHER
Intervention: Placing a self-expanding metallic stent
Description: * Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: A balloon dilatation
Description: * Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required\> 2 expansions.
Study: NCT04071951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led Hospital Discharge Care Intervention
Description: Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone.
Study: NCT03735420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
Study: NCT02444741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT
Study: NCT04456699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID, oral until progressive disease or end of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID, oral until progressive disease or end of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin/ levoleucovorin
Description: 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
Study: NCT04079933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral tobacco-derived nicotine product (OTDN)
Study: NCT01717573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred stenting

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Study: NCT04508803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib
Description: Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib
Description: Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib，Trastuzumab
Description: Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib，Pyrrolitinib
Description: HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle.
Study: NCT03193294

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
Study: NCT04040972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion Focussed Therapy
Description: Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
Study: NCT03588169

Intervention type: DIETARY_SUPPLEMENT
Intervention: semi-structured interviews
Description: About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it
Study: NCT03731494

Intervention type: BIOLOGICAL
Intervention: Nickel oral hyposensitization treatment
Description: Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
Study: NCT01025700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesemat
Description: 1 mg capsule per day for 21 days
Study: NCT03030612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered subcutaneously/intravenously.